SCHEMBL6404162

SCHEMBL6404162

CC(CCc1ccc(O)cc1OP(=O)(O)O)c1cccc(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.42
TYR P14679 2/20 0.37
F2 P00734 3/20 0.35
INPPL1 O15357 1/20 0.35
INPP5B P32019 1/20 0.35
INPP5A Q14642 1/20 0.35
HTR2B P41595 3/20 0.35
ADRB1 P08588 2/20 0.35
ADRA1A P35348 2/20 0.35
MIF P14174 1/20 0.35
HTR2C P28335 2/20 0.34
HTR1A P08908 2/20 0.33
HIF1A Q16665 2/20 0.33
POLB P06746 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRB3 P13945 1/20 0.33
TSHR P16473 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397756 0.90 HTR2A (0.42) HTR2ATYRINPPL1INPP5BINPP5A
SCHEMBL6396578 0.89 F2 (0.41) HTR2ATYRF2INPPL1INPP5B
SCHEMBL6396983 0.88 INPPL1 (0.36) HTR2AINPPL1INPP5BINPP5AHTR2B
SCHEMBL6394492 0.83 HTR2A (0.36) HTR2AINPPL1INPP5BINPP5AHTR2B
SCHEMBL6398534 0.82 HTR2A (0.39) HTR2ATYRINPPL1INPP5BINPP5A
SCHEMBL6403628 0.81 TYR (0.39) HTR2ATYRHTR2BADRB1ADRA1A
SCHEMBL6401818 0.80 INPPL1 (0.36) HTR2AINPPL1INPP5BINPP5AHTR2B
SCHEMBL6401534 0.79 HTR2A (0.39) HTR2ATYRF2INPPL1INPP5B
SCHEMBL6394487 0.79 ADRB1 (0.37) HTR2ATYRHTR2BADRB1ADRA1A
SCHEMBL6397679 0.78 ESR1 (0.38) HTR2AINPPL1INPP5BINPP5AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 HTR2A 2756/4885TYR 3689/4885F2 3040/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 HTR2A 2925/4885TYR 3556/4885F2 2987/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 HTR2A 2756/4885TYR 3689/4885F2 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.